The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions - Mini Focus on Antithrombotic Therapy

Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial

EuroIntervention 2021;16:1163-1169. DOI: 10.4244/EIJ-D-20-00268

1. Department of Cardiology, University Hospital of Heraklion, Crete, Greece; 2. Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; 3. 1st Cardiology Department, AHEPA University Hospital, Thessaloniki, Greece; 4. 3rd Cardiology Department, Hippokration Hospital, Thessaloniki, Greece; 5. 1st Cardiology Department, Ioannina University Hospital, Ioannina, Greece; 6. 2nd Cardiology Department, Ioannina University Hospital, Ioannina, Greece; 7. 1st Cardiology Department, Red Cross General Hospital, Athens, Greece; 8. 2nd Cardiology Department, Red Cross General Hospital, Athens, Greece; 9. Cardiology Department, Gennimatas General Hospital, Athens, Greece; 10. Cardiology Department, Democritus University of Thrace, Alexandroupolis, Greece; 11. Cardiology Department, Patras University Hospital, Rio, Greece; 12. Hellenic Cardiovascular Research Society (HCRS), Athens, Greece

Aims: We aimed to demonstrate whether coronary microvascular function is improved after ticagrelor administration compared to clopidogrel administration in STEMI subjects undergoing thrombolysis.

Methods and results: MIRTOS is a multicentre study of ticagrelor versus clopidogrel in STEMI subjects treated with fibrinolysis. We enrolled 335 patients <75 years old with STEMI eligible for thrombolysis, of whom 167 were randomised to receive clopidogrel and 168 to receive ticagrelor together with thrombolysis. Primary outcome was the difference in post-PCI corrected TIMI frame count (CTFC). All clinical events were recorded in a three-month follow-up period. From the 335 patients who were randomised, 259 underwent PCI (129 clopidogrel and 130 ticagrelor) and 154 angiographies were analysable for the study primary endpoint. No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10). No significant differences were observed in MACE and major bleeding events between randomisation groups (OR 2.0, 95% CI: 0.18-22.2, p=0.99).

Conclusions: Thrombolysis with ticagrelor in patients <75 years old was not able to demonstrate superiority compared to clopidogrel in terms of microvascular injury, while there was no difference between the two groups in MACE and major bleeding events. Trial Registration. Identifier: NCT02429271. EudraCT Number 2014-004082-25.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
A prospective, multicentre, randomised, open-label trial to compare the efficacy and safety of clopidogrel versus ticagrelor in stabilised patients with acute myocardial infarction after percutaneous coronary intervention: rationale and design of the TALOS-AMI trial